BioLargo, Inc.
BLGO · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.69 | 0.51 | 0.27 | 0.16 |
| FCF Yield | -7.84% | -5.92% | -5.80% | -7.65% |
| EV / EBITDA | -13.71 | -11.03 | -10.18 | -7.77 |
| Quality | ||||
| ROIC | -91.03% | -71.15% | -147.14% | -308.86% |
| Gross Margin | 44.17% | 50.32% | 48.56% | 43.58% |
| Cash Conversion Ratio | 0.74 | 0.67 | 0.54 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 44.57% | 69.06% | 34.25% | 10.79% |
| Free Cash Flow Growth | -56.21% | 6.26% | 23.62% | 4.93% |
| Safety | ||||
| Net Debt / EBITDA | 0.24 | 0.44 | 0.08 | -0.03 |
| Interest Coverage | -31.16 | -46.00 | -96.58 | -27.27 |
| Efficiency | ||||
| Inventory Turnover | 30.08 | 39.71 | 25.23 | 5.93 |
| Cash Conversion Cycle | 37.72 | 6.23 | -28.41 | 8.04 |